Se espera que el mercado del tratamiento de la vejiga hiperactiva crezca de 4.295,93 millones de dólares en 2021 a 5.333,92 millones de dólares en 2028; se estima que crecerá a una tasa compuesta anual del 3,1 % entre 2022 y 2028.
La vejiga hiperactiva (VH) es la necesidad frecuente y repentina de orinar, que puede ser difícil de controlar. La OAB puede ser causada por un traumatismo abdominal, infección, daño a los nervios y ciertos medicamentos. La OAB es común en personas de 65 años o más. Las mujeres pueden tener VHA después de los 45 años. El tratamiento incluye cambiar ciertos comportamientos, medicamentos y estimulación nerviosa.
El mercado del tratamiento de la vejiga hiperactiva está segmentado en farmacoterapia, tipo de enfermedad y geografía. Por geografía, el mercado está ampliamente segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y el Sur y el Sur. Centroamérica. El informe de mercado de Tratamiento de vejiga hiperactiva ofrece información y un análisis en profundidad del mercado, enfatizando parámetros como las tendencias del mercado, la dinámica del mercado y el análisis competitivo de los principales actores del mercado a nivel mundial.
Información estratégica Regiones lucrativas para el mercado del tratamiento de la vejiga hiperactiva
Perspectivas del mercado
Según datos de la Asociación Nacional para la Incontinencia, en 2018, ~200 millones de personas en todo el mundo se vieron afectadas por la incontinencia urinaria . La incontinencia de esfuerzo y la incontinencia de urgencia son los dos tipos comunes de incontinencia urinaria que afectan a las mujeres, siendo esta última también conocida como vejiga hiperactiva. De manera similar, un estudio realizado por un grupo de investigadores del Colegio Estadounidense de Médicos y la Sociedad de Enfermedades Infecciosas de América en 2020 afirmó que la infección del tracto urinario (ITU) era la causa de ~6 millones de visitas al médico cada año en los EE. UU. En Canadá, aproximadamente 500.000 visitas al consultorio médico al año son para consultas de ITU. Las ITU son la octava y quinta razón más común de visitas a clínicas ambulatorias y visitas a departamentos de emergencia, respectivamente, en el país. Por lo tanto, la creciente prevalencia de la incontinencia urinaria y la creciente incidencia de infecciones del tracto urinario están impulsando el mercado del tratamiento de la vejiga hiperactiva.
A continuación se muestran algunos ejemplos de lanzamientos y aprobaciones de nuevos productos:
- En febrero de 2022, Alembic Pharmaceuticals recibió la aprobación del regulador sanitario de EE. UU. para su versión genérica de tabletas de liberación prolongada de fumarato de fesoterodina, utilizadas para la vejiga hiperactiva en adultos con síntomas de incontinencia urinaria, urgencia y frecuencia urinaria. La aprobación por parte de US Food & Administración de Medicamentos (USFDA) para la solicitud abreviada de nuevo medicamento (ANDA) para tabletas de liberación prolongada de fumarato de fesoterodina es para concentraciones de 4 mg y 8 mg.
- En abril de 2022, Axonics, Inc., una tecnología médica global La empresa que desarrolla y comercializa productos novedosos para el tratamiento de la disfunción de la vejiga y los intestinos anunció el lanzamiento integral del Axonics F15 en los EE. UU. El sistema de neuromodulación sacra (SNM) recién desarrollado, de larga duración y totalmente libre de recarga recibió la aprobación de la FDA en marzo. El sistema sin recarga de Axonics es un avance bienvenido para los pacientes que padecen disfunción de la vejiga y los intestinos.
- En marzo de 2021, Myrbetriq de Astellas Pharma, utilizado para el tratamiento de la hiperactividad neurogénica del detrusor (NDO) en pacientes pediátricos de tres años. años y mayores (que pesen 35 kg o más), y Myrbetriq Granules, para el tratamiento de NDO en pacientes pediátricos de tres años o más, fueron aprobados por la Administración de Medicamentos y Alimentos de EE. UU. (FDA).
Estos desarrollos de productos por parte de los actores del mercado están impulsando el mercado del tratamiento de la vejiga hiperactiva.
Type Insights
Basado en la farmacoterapia, el mercado del tratamiento de la vejiga hiperactiva está segmentado en mirabegrón, botox , neuroestimulación, anticolinérgicos e instilación intravesical. El segmento de mirabegrón tuvo la mayor participación del mercado en 2021 y se prevé que registre la CAGR más alta durante el período de pronóstico. Mirabegrón se usa solo o con solifenacina para tratar la vejiga hiperactiva en adultos. Se utiliza para tratar la hiperactividad neurogénica del detrusor (una afección de control de la vejiga causada por un problema del cerebro, la médula espinal o los nervios) en niños de tres años o más. Mirabegrón pertenece a la clase de medicamentos llamados agonistas adrenérgicos beta-3. Relaja los músculos de la vejiga para prevenir la micción urgente, frecuente o incontrolada. Mirabegron está disponible en forma de tableta de liberación prolongada (acción prolongada) y suspensión de liberación prolongada que se puede tomar por vía oral. En octubre de 2022, Zydus Pharmaceuticals Inc. recibió la aprobación de la USFDA para comercializar tabletas de liberación prolongada Mirabegron USP 25. mg y 50 mg. Se espera que la creciente demanda de esta terapia impulse el crecimiento del mercado de tratamiento de la vejiga hiperactiva durante el período de pronóstico.
Mercado de tratamiento de la vejiga hiperactiva, por tipo: 2021 y 2028
Información sobre servicios
Basado en la farmacoterapia, el mercado del tratamiento de la vejiga hiperactiva se segmenta en mirabegrón, Botox, neuroestimulación, anticolinérgicos e instilación intravesical. Se prevé que el segmento de neuroestimulación registre la CAGR más alta del mercado durante el período de pronóstico. El control neurológico de la vejiga es complejo y depende de diferentes nervios espinales, centrales y periféricos, y de sus múltiples vías reflejas. El control neurológico se realiza en diferentes partes del cuerpo humano y, por lo tanto, se dirige a varios nervios. Algunos de estos nervios diana están directamente involucrados en el control sensomotor del tracto urinario inferior, como los nervios sacros o pudendos, mientras que otros están involucrados de manera más indirecta. La estimulación eléctrica se utiliza para activar estos nervios para controlar la vejiga.
Las asociaciones y colaboraciones son estrategias muy adoptadas por los actores del mercado mundial del tratamiento de la vejiga hiperactiva. A continuación se enumeran algunos de los acontecimientos clave recientes del mercado:
- En abril de 2021, Medtronic plc anunció la aprobación de la Administración de Medicamentos y Alimentos de EE. UU. (FDA) para proceder con un ensayo de exención de dispositivo en investigación (IDE) para evaluar su dispositivo implantable de neuromodulación tibial (TNM) desarrollado internamente, una terapia diseñada para aliviar los síntomas de la incontinencia vesical.
- En julio de 2020, Hisamitsu Pharmaceutical Co. ., Inc. anunció la aprobación de la fabricación y comercialización de OABLOK PATCH en Tailandia. El producto es una formulación transdérmica sistémica desarrollada utilizando la tecnología del sistema de administración transdérmica de fármacos (TDDS) de Hisamitsu para tratar la vejiga hiperactiva con síntomas como urgencia urinaria y micción frecuente.
- En julio de 2019, se lanzó Teva Pharmaceuticals Ltd. Solifenacina Succinato Tabletas, que son antagonistas muscarínicos indicados para el tratamiento de la vejiga hiperactiva con síntomas de incontinencia urinaria y aumento de la frecuencia urinaria.
La pandemia de COVID-19 ha mostrado algunos escenarios favorables para los jugadores que operan en el mercado del tratamiento de la vejiga hiperactiva. Estados Unidos fue el país más afectado de América del Norte. La infección afectó gravemente a la población geriátrica del país, provocando diversas complicaciones y provocando la muerte de una gran población. Por ejemplo, al 16 de mayo de 2022, EE. UU. informó 84.230.829 casos de COVID y 1.026.670 muertes. Por lo tanto, se requiere un tratamiento de la vejiga hiperactiva y una atención adecuada para prevenir casos crónicos de infección y problemas de salud.
Después del brote de COVID-19, ha habido un aumento en la aparición de VHA. Según Según un estudio de la Asociación Estadounidense de Urología, los pacientes con infecciones por COVID-19 tenían un mayor riesgo de desarrollar síntomas de vejiga hiperactiva nuevos o que empeoraran. Además, aproximadamente un tercio de los pacientes con COVID-19 informaron un aumento significativo de los síntomas clínicos durante la Consulta Internacional sobre el Módulo de Vejiga Hiperactiva del Cuestionario de Incontinencia (ICIQ-OAB) realizada dos meses después de la infección. De este tercio de los pacientes, aproximadamente 1 de cada 5 pacientes informó que sus síntomas de VHA eran nuevos. Este aumento de la prevalencia de VHA debido a la COVID-19 tuvo un impacto positivo en la demanda de tratamiento de la vejiga hiperactiva durante la pandemia.
Tratamiento de la vejiga hiperactiva: tratamiento de la vejiga hiperactiva: Segmentación del mercado
El mercado global de tratamiento de la vejiga hiperactiva se analiza en función de la farmacoterapia, el tipo de enfermedad y la geografía. Según la farmacoterapia, el mercado de tratamiento de la vejiga hiperactiva se clasifica en mirabegrón, Botox, neuroestimulación, anticolinérgicos e instilación intravesical. Según el tipo de enfermedad, el mercado se divide en vejiga hiperactiva idiopática y vejiga neurogénica. Geográficamente, el mercado del tratamiento de la vejiga hiperactiva está segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y el Sur y el Sur. Centroamérica.
Perfiles de la empresa
- Alembic Pharmaceuticals Limited
- Astellas Pharma Inc
- AbbVie Inc
- Teva Pharmaceuticals Industries Ltd
- Endo Pharmaceuticals Inc
- Hisamitsu Pharmaceutical Co. Inc
- Medtronic Plc
- Colorado Urology Associates, PLLC
- Tecnologías de modulación Axonics, Inc
- Pfizer Inc
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The mirabegron segment held the largest share of the market in 2021. However, neurostimulation is expected to grow at the highest CAGR during the forecast period.
The Asia Pacific is expected to be the fastest-growing region in the overactive bladder treatment market over the forecast period due to the rising geriatric population, increasing urinary incontinence cases, and a surge in product launches.
The CAGR value of the overactive bladder treatment market during the forecasted period of 2022-2028 is 3.1%.
The overactive bladder treatment market is estimated to be valued at US$ 4,295.93 million in 2021.
The overactive bladder treatment market is expected to be valued at US$ 5,333.92 million in 2028.
The overactive bladder treatment market majorly consists of the players, such as Alembic Pharmaceuticals Limited, Astellas Pharma Inc; Pfizer Inc; AbbVie Inc; Teva Pharmaceutical Industries Ltd; Endo Pharmaceuticals Inc; Hisamitsu Pharmaceutical Co., Inc; Medtronic Plc; Colorado Urology Associates, PLLC; Axonics Modulation Technologies, Inc.
The factors that are driving the growth of the overactive bladder treatment market are urinary tract infections (UTI) which lead to increased activity in the bladder wall muscles, causing symptoms like an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities may further damage the integrity of the urothelial barrier. The increasing prevalence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the overactive bladder treatment market growth.
The sudden need to urinate causes a problem with bladder dysfunction. An overactive bladder may affect how often you pee and your urgency. Causes include abdominal trauma, infection, nerve damage, medications, and certain fluids. Treatment includes changing certain behaviors, medications, and nerve stimulation. Overactive bladder is common in people aged 65 and older. Women may have OAB at a younger age, usually around 45.
The List of Companies -Overactive Bladder Treatment Market
- Alembic Pharmaceuticals Limited
- Astellas Pharma Inc
- Pfizer Inc
- AbbVie Inc
- Teva Pharmaceutical Industries Ltd
- Endo Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co.,Inc
- Medtronic Plc
- Colorado Urology Associates, PLLC
- Axonics Modulation Technologies, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Oct 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Oct 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Oct 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)